Rydex Biotechnology Fund Class H (RYOAX)

77.36
Net Asset Value
-0.78%
1 Day
-1.31%
Year-to-Date
Overall Morningstar Rating
Health
Style or Category
No Load
Sales Expenses
1.61%
Expense Ratio
High
Morningstar Risk Rating™
Investment Objective The investment seeks to provide capital appreciation. Under normal circumstances- the fund invests substantially all (at least 80%) of its net assets in equity securities of Biotechnology Companies that are traded in the United States and in derivatives- which primarily consist of futures contracts and options on securities- futures contracts- and stock indices. It may invest to a significant extent in the securities of Biotechnology Companies that have small to mid-sized capitalizations. The fund is non-diversified.

Performance

1 month-6.25% 3 years-1.99%
3 months-5.06% 5 years+12.45%
1 year+14.27% Since inception+11.50%
Data through --

Peer Comparisonvs. Health

 RYOAXCategory
Performance 5-yr return+12.45%+14.29%
Expense ratio1.61%1.30%
Risk 5 year sharpe ratio0.660.92
Net assets$294.1M$3.0B
Average market cap$12.7B$10.0B
Average P/E32.222.2
Portfolio turnover207%207%

There are thousands of mutual funds to choose from. Get Money Magazine’s picks in all major categories.

Fund Management and Purchase Info

Fund familyRydex Funds
Fund manager & tenureMichael Byrum / 20 Years
Minimal initial investment$2,500.00
Minimum IRA investment$1,000.00

Holdings

U.S. stock94.09%
Cash3.68%
Fixed income2.23%
International stock0.00%
Other0.00%
Top 5 Sectors
Portfolio weighting
Healthcare 100.00%
Business service 0.00%
Consumer goods 0.00%
Consumer service 0.00%
Energy 0.00%
Top 10 Holdings
Portfolio weighting
ABBV AbbVie5.74%
AMGN Amgen5.51%
GILD Gilead Sciences5.05%
CELG Celgene4.23%
BIIB Biogen3.92%
VRTX Vertex Pharmaceuticals Inc3.25%
REGN Regeneron Pharmaceuticals3.22%
ILMN Illumina Inc3.02%
ALXN Alexion Pharmaceuticals Inc2.46%
NKTR Nektar Therapeutics2.15%